{
Zydus Lifesciences Limited

Companies

}
001122334455554433221100
001122334455554433221100

Global Generic Pharmaceuticals Market Sees Growth in Simple Generics and Biosimilars

India's "Pharmaceuticals Mission" aims to boost generic production, with simple generics leading the market due to cost-effectiveness and ease of manufacturing. Cardiovascular diseases drive demand, while small molecules dominate product types. Retail pharmacies remain the preferred distribution channel, and key players like Cipla and Teva are expanding their offerings.
GlobeNewswire News Room
United States Dollar Euro Fresenius Kabi AG Sanofi Aspen Pharmacare Holdings Ltd Sun Pharmaceuticals, Ltd. Aurobindo Pharma Limited Glenmark Pharmaceuticals Limited Pfizer Inc. Lupin Limited Dr. Reddy's Laboratories Limited Zydus Lifesciences Limited Teva Pharmaceuticals, Inc. Viatris Inc. Novartis AG Hikma Cipla Limited IND USA Show more
Healthcare, Market Report
16:30 04.12.2024

Zydus Lifesciences reports mixed quarterly results but maintains buy rating

Zydus Lifesciences reported a revenue of Rs. 5,237 crore, a 20% year-on-year increase, but a 16% quarter-on-quarter decline, largely due to weaker performance in the Indian consumer wellness segment and US formulations. EBITDA rose 28% year-on-year to Rs. 1,461 crore, though it fell 30% quarter-on-quarter, with margins at ~28%. The company reaffirmed a Buy rating with a target price of Rs. 1,078, trading at 22x and 20x its FY26E and FY27E EPS, respectively.
Moneycontrol
Indian Rupee Zydus Lifesciences Limited IND
Finance & Economy, Market Report
09:00 19.11.2024

zydus lifesciences reports strong performance but faces future challenges

Zydus LifeSciences reported a 19% YoY revenue growth, below the expected 25%, but achieved better-than-anticipated margins due to improved performance in the US and international markets. Motilal Oswal raised earnings estimates for FY25E/FY26E/FY27E by 3%/4%/3%, respectively, while maintaining a Neutral rating and a target price of INR 1,010, citing stable earnings outlook despite increased competition and higher tax rates.
Moneycontrol
Indian Rupee Zydus Lifesciences Limited IND Motilal Oswal
Finance & Economy, Market Report
12:43 14.11.2024

Zydus Lifesciences maintains accumulate rating with revised target price of 1050

Zydus Lifesciences reported a Q2 EBITDA of Rs 14.2 billion, reflecting a 33% year-on-year increase, aligning with estimates. Despite a 25% stock price correction over three months due to product concentration risks and competition, the company’s strong domestic presence and a robust pipeline of complex products are expected to drive future growth. Prabhudas Lilladher maintains an 'Accumulate' rating with a revised target price of Rs 1,050, valuing the stock at 25 times FY27E EPS.
Moneycontrol
United States Dollar Zydus Lifesciences Limited IND Prabhudas Lilladher
Healthcare, Market Report
07:57 13.11.2024

Zydus Lifesciences gains WHO approval for ZyVac TCV vaccine

Zydus Lifesciences' shares rose over 2% following the company's receipt of in-principle approval from the WHO for its ZyVac TCV vaccine, making it eligible for UN procurement. The stock has gained over 44% year-to-date, significantly outperforming the Nifty 50 index. ZyVac TCV is an indigenously developed typhoid vaccine for individuals aged 6 months to 65 years, manufactured at Zydus Biotech Park in Ahmedabad.
Moneycontrol
Indian Rupee Zydus Lifesciences Limited IND
Healthcare, Market Report
08:49 23.10.2024
Trending
Subcategory
Corporate News Industry Trends Stock Market Updates Retail and Consumer Goods Startups & Entrepreneurship CEO Changes Financial Scams and Security Banking Regulations Global Financial Events Finance Mergers & Acquisitions Market Analysis and Predictions Industry Mergers & Acquisitions Central Bank Actions Hedge Funds & Private Equity Workplace Trends Global Trade Developments Government Economic Policies Corporate Social Responsibility AI Innovations Supply Chain Management
Countries:
USA CHN IND GBR JPN CHE SGP ARE QAT IDN SAU DEU MYS KOR CAN KWT VNM THA ISR NLD
Companies:
Wells Fargo & Company The Goldman Sachs Group, Inc. Tesla, Inc. Barclays PLC Bank of America Corporation NatWest Group plc Apple Inc. JPMorgan Chase & Co. Lloyds Banking Group plc Mastercard Inc Visa Inc. Santander UK plc Morgan Stanley Mercedes-Benz Group AG Amazon.com, Inc. OpenAI ERC USD Tiktok USD DoorDash, Inc. Deliveroo plc Nissan Motor Co., Ltd.
Currencies:
United States Dollar Chinese Yuan British Pound Sterling Euro Swiss Franc Japanese Yen Indonesian Rupiah Indian Rupee Offshore Chinese Yuan United Arab Emirates Dirham Singapore Dollar Qatari Riyal South Korean Won Jordanian Dinar Brazilian Real
People:
Donald Trump Elon Musk Rachel Reeves Warren Buffett Jamie Dimon Charlie Nunn Georges Elhedery Mike Regnier Paul Thwaite Hidenori Tanaka Andrew Bailey Joe Biden Jean Du Boullay Raoul Pal Rosan Roeslani Prabowo Subianto Moeldoko Patrick P. Gelsinger Michael Beckerman Mu Qing

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.